Abstract 1808P
Background
In CABASTY trial (NCT02961257), CBZ 16 mg/m2 q2w + G-CSF significantly reduced grade ≥3 neutropenia and/or neutropenic complications vs CBZ 25 mg/m2 q3w + G-CSF with comparable overall survival (OS) benefit in older and heavily pretreated patients (pts) with mCRPC (Oudard et al. ESMO 2022). Here, we report changes in HRQL in both arms during therapy.
Methods
The Functional Assessment Cancer Therapy-Prostate (FACT-P) questionnaire was collected at each visit and analyzed in all pts exposed to CBZ with evaluable HRQL at baseline and post-baseline. Higher values indicated better HRQL. Changes of ≥10 points in FACT-P total score and ≥2 points in Prostate Cancer Subscale (PCS)-pain score, confirmed by 2 consecutive evaluations were judged clinically meaningful.
Results
196 pts (median age, 74.6 yrs; ≥75 yrs, 49%; G8 <14, 20%; vulnerable or frail per SIOG guidelines, 30.1%; moderate to severe pain, 18%) previously treated with docetaxel and novel hormonal therapies (median 3 lines) were randomized to CBZ q3w (n=97) or q2w (n=99) + G-CSF. Median treatment duration was 19.0 and 20.1 weeks with CBZ q3w and q2w, respectively. HRQL was evaluable in 88 (90.7%) and 96 (97.0%) pts with CBZ q3w and q2w. PCS-pain improved in 35.2% vs 38.5% (CBZ q3w vs q2w). The probability of not having PCS-pain deterioration during treatment was 81.8% vs 75.0% with CBZ q3w vs q2w (HR=1.5 [95% CI, 0.80-2.9], p=0.2). Total FACT-P score improved from baseline in 17.0% vs 13.5% of pts with CBZ q3w vs q2w, respectively. FACT-P score was either stable or improved from baseline in 75.0% vs 74.0% of pts with CBZ q3w vs q2w. At 75% percentile, time to deterioration was 4.9 vs 3.3 months (HR: 1.2; p =0.57) with CBZ q3w vs q2w.
Conclusions
In this older and heavily pretreated mCRPC pts population, CBZ q3w and q2w + G-CSF similarly relieved pain and maintained or improved HRQL in 3 out of 4 pts with a comparable OS benefit. Since bi-weekly dosing induces less grade ≥3 neutropenia and/or neutropenic complications, it should be offered to pts unfit to receive the standard CBZ regimen.
Clinical trial identification
NCT02961257.
Editorial acknowledgement
Legal entity responsible for the study
ARTIC.
Funding
Sanofi.
Disclosure
S. Oudard: Financial Interests, Personal and Institutional, Advisory Board: Sanofi, Bayer, Janssen, AstraZeneca; Financial Interests, Personal, Advisory Board: Astellas, Pfizer. R. Ratta: Financial Interests, Personal, Invited Speaker: Ipsen, Astellas; Financial Interests, Personal, Advisory Board: Pfizer, Merck, BMS, AstraZeneca, Janssen. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen. A. Thiery-Vuillemin: Financial Interests, Personal, Advisory Board, & public speaking: Pfizer, AstraZeneca, Janssen, Ipsen, BMS; Financial Interests, Personal, Advisory Board: Sanofi, Novartis, Roche/Genentech, MSD, Astellas Pharma; Financial Interests, Personal, Full or part-time Employment, since 2023: BMS; Financial Interests, Institutional, Funding: Pfizer, Ipsen, Bayer; Financial Interests, Institutional, Local PI: Pfizer, AstraZeneca, Sanofi, JNJ, Novartis, Ipsen, Roche, BMS, MSD, Astellas Pharma, Excelixis, UNICANCER/GETUG, Incyte; Financial Interests, Steering Committee Member: AstraZeneca, Novartis, BMS; Non-Financial Interests, Member: ASCO, GETUG; Other, Other, Travel, Accommodations: Roche, MSD, JNJ, BMS, AstraZeneca, Pfizer, Astellas Pharma, Ipsen. K. Aldabbagh: Financial Interests, Personal, Advisory Board: Ipsen, Janssen, Novartis, Pfizer. C. Saldana: Financial Interests, Personal, Advisory Board: BMS, Ipsen, Pfizer, Bayer. G. Von Amsberg: Financial Interests, Personal, Advisory Board: Roche, BMS, Astellas, Sanofi, Janssen, MSD, Ipsen, Pfizer, AstraZeneca, Merck, Eisai. N. Houede: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, BMS, Merck, Pfizer, MSD, Janssen. D. Vernerey: Financial Interests, Personal, Advisory Board: SAS Novis, CellProtera SAS, Apmonia Therapeutics, Incyte, Veracyte SAS, INVECTYS, Novartis. C. Helissey: Financial Interests, Personal, Advisory Board: Janssen, Roche, Sanofi, Astellas, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14